Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.

This review article describes three aspects of polymeric drugs. The general mechanism of the EPR (enhanced permeability and retention) effect and factors involved in the effect are discussed, in view of the advantages of macromolecular therapeutics for cancer treatment, which are based on the highly selective EPR-related delivery of drug to tumor. Also described are advantages of more general water-soluble polymeric drugs as primary anticancer agents, using SMANCS as an example. Last, SMANCS/Lipiodol is discussed with reference to the type of formulation for arterial injection with most pronounced tumor selective delivery, as well as its advantages, precautions, and side effects from the clinical standpoint.

[1]  H. Maeda,et al.  Reduction of hepatic metastases in rabbits by administration of an oily anticancer agent into the portal vein. , 1987, Cancer research.

[2]  H. Maeda.  The tumor blood vessel as an ideal target for macromolecular anticancer agents , 1992 .

[3]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[4]  H. Maeda,et al.  Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. , 1984, Cancer research.

[5]  H. Yamanaka,et al.  Tumor-targeted chemotherapy with SMANCS in lipiodol for renal cell carcinoma: longer survival with larger size tumors. , 2000, Urology.

[6]  Polymer Conjugation to Cu,Zn-SOD and Suppression of Hydroxyl Radical Generation on Exposure to H2O2: Improved Stability of SOD in Vitro and in Vivo , 1996 .

[7]  H. Maeda,et al.  Interferon induction by SMANCS: a polymer-conjugated derivative of neocarzinostatin. , 1988, Anticancer research.

[8]  H. Maeda,et al.  Enhancement by Verapamil of Neocarzinostatin Action on Multidrug‐resistant Chinese Hamster Ovary Cells: Possible Release of Nonprotein Chromophore in Cells , 1991, Japanese journal of cancer research : Gann.

[9]  S. Maki,et al.  Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium , 1985, Cancer.

[10]  S. Tashiro,et al.  Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. , 1983, European journal of cancer & clinical oncology.

[11]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.

[12]  H. Maeda,et al.  Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. , 1988, The Journal of biological chemistry.

[13]  T. Konno,et al.  Targeted chemotherapy for unresectable primary and metastatic liver cancer. , 1994, Acta oncologica.

[14]  W. Regelson,et al.  The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. , 1986, Cancer investigation.

[15]  Toshimitsu Konno,et al.  Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on smancs , 1984 .

[16]  M. Ueda,et al.  Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. , 1985, Journal of medicinal chemistry.

[17]  J. Whitaker,et al.  Protein tailoring for food and medical uses , 1986 .

[18]  Hiroshi Maeda,et al.  A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. , 2009, International journal of peptide and protein research.

[19]  H. Maeda,et al.  Kallikrein-kinin in infection and cancer. , 1999, Immunopharmacology.

[20]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[21]  H. Maeda,et al.  Host-Mediated Antitumor Activity Induced by Neocarzinostatin and Its Polymer-Conjugated Derivative SMANCS in Tumor-Bearing Mice , 1997 .

[22]  T. Konno.  Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol. , 1992, European journal of cancer.

[23]  H. Maeda,et al.  Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. , 1990, Cancer research.

[24]  K. Ulbrich,et al.  Preclinical evaluation of polymer-bound doxorubicin , 1992 .

[25]  H. Maeda,et al.  Enhanced Vascular Permeability in Solid Tumor Involving Peroxynitrite and Matrix Metalloproteinases , 2001, Japanese journal of cancer research : Gann.

[26]  K. Hori,et al.  A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. , 1981, Journal of the National Cancer Institute.

[27]  H. Maeda,et al.  Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth , 1996, Cancer.

[28]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[29]  R. Duncan,et al.  Polymer Conjugates , 1994 .

[30]  H. Maeda,et al.  Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin. , 1990, Cancer research.

[31]  H. Maeda,et al.  Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. , 2000, Cancer research.

[32]  H. Maeda,et al.  Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer. , 1987, Cancer research.

[33]  H. Maeda,et al.  Stimulation of Macrophage by Polyanions and Its Conjugated Proteins and Effect on Cell Membrane 1 , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[34]  W. Shen.  Neocarzinostatin: The past, present, and future of an anticancer drug , 2000 .

[35]  H. Maeda,et al.  Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. , 1998, Cancer research.

[36]  H. Maeda,et al.  Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. , 1993, British Journal of Cancer.

[37]  H. Maeda,et al.  SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.

[38]  S. Tashiro,et al.  Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium , 1984, Cancer.

[39]  H. Maeda,et al.  Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. , 1987, Journal of the National Cancer Institute.

[40]  Hiroshi Maeda,et al.  Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.

[41]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[42]  D. Kerr,et al.  A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma. , 1998, International journal of oncology.

[43]  H. Maeda,et al.  Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.

[44]  J. Kopeček,et al.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[45]  H. Maeda,et al.  Enhanced Vascular Permeability in Solid Tumor Is Mediated by Nitric Oxide and Inhibited by Both New Nitric Oxide Scavenger and Nitric Oxide Synthase Inhibitor , 1994, Japanese journal of cancer research : Gann.

[46]  K. Ulbrich,et al.  Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. , 1994, British Journal of Cancer.